Thyroid-stimulating hormone and clinical outcomes: The CORONA trial (controlled rosuvastatin multinational study in heart failure) by Perez, Ana Cristina et al.
JACC: Heart Failure Vol. 2, No. 1, 2014
 2014 by the American College of Cardiology Foundation ISSN 2213-1779/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jchf.2013.07.008CLINICAL RESEARCH
Thyroid-Stimulating Hormone and
Clinical Outcomes
The CORONA Trial (Controlled Rosuvastatin Multinational
Study in Heart Failure)
Ana Cristina Perez, MD,* Pardeep S. Jhund, MB, PHD,* David J. Stott, MD,y
Lars Gullestad, MD, PHD,z John G. F. Cleland, MD,x Dirk J. van Veldhuisen, MD, PHD,k
John Wikstrand, MD, PHD,{ John Kjekshus, MD, PHD,z John J. V. McMurray, MD*
Glasgow, Scotland; Oslo, Norway; Kingston-Upon-Hull, United Kingdom;
Groningen, the Netherlands; and Gothenburg, SwedenFrom the *B
Scotland; yD
Royal Inﬁrm
Hospital, Ri
Heart Failur
York Medic
Centre, Gro
vascular Re
Sweden. DObjectives THF Cardiovascular Rese
epartment of Academic
ary, Glasgow, Scotland;
kshospitalet, and K. G. J
e Research, Faculty of Me
al School, Kingston-Upo
ningen, the Netherlands;
search, Sahlgrenska Aca
r. Perez was supported bhis study sought to examine the association between thyroid status and clinical outcomes in patients in the
CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) study.Background Hypo- and hyperthyroidism were associated with worse clinical outcomes in the SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial).Methods In CORONA, 4,987 patients underwent baseline thyroid-stimulating hormone (TSH) measurement, 237 of
which (4.8%) were receiving thyroid replacement therapy (TRT). Patients were classiﬁed as euthyroid (TSH: 0.3 to
5.0 mU/ml, and no TRT), hyperthyroid (<0.3 mU/ml and no TRT), or hypothyroid (>5.0 mU/ml and no TRT). The
outcome composites of cardiovascular (CV) death or hospitalization for heart failure (HF), the components of this
composite, and all-cause death were compared among hyperthyroid, hypothyroid, and euthyroid states, using
multivariable models adjusting for previously reported prognostic variables.Results A total of 91.3% of patients were euthyroid, 5.0% were hypothyroid, and 3.7% were hyperthyroid. Compared with
euthyroid patients, hypothyroid patients were more likely to have a history of stroke, had worse renal function
and higher N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, were more likely to be treated with an
antiarrhythmic drug (or have an implantable cardioverter deﬁbrillator), and were less likely to smoke or be treated
with a beta-blocker or angiotensin-converting enzyme inhibitor/angiotensin receptor blocker. In univariate analyses,
hypothyroidism was associated with an increased risk of the composite outcome of CV death or HF hospitalization
(hazard ratio: 1.29; 95% conﬁdence interval: 1.07 to 1.57; p ¼ 0.008), as well as all-cause death (HR: 1.36; 95%
conﬁdence interval: 1.03 to 1.76; p ¼ 0.004). However, after adjustment for other known predictors of outcome, the
associations were weakened, and when NT-proBNP was added to the models, the association between
hypothyroidism and all outcomes was eliminated.Conclusions Thyroid status is not an independent predictor of outcome in heart failure with reduced ejection fraction. (Controlled
Rosuvastatin Multinational Study in Heart Failure [CORONA]; NCT00206310) (J Am Coll Cardiol HF 2014;2:35–40)
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36SCD-HeFT (Sudden Cardiac
Death in Heart Failure Trial) (1–
3). The SCD-HeFT investigators
reported that both elevated and
suppressed thyroid-stimulating
hormone (TSH) levels were asso-
ciated with an increased risk of
death, even after adjusting for other
prognostic variables (4). We have
now examined the same question
in the CORONA (Controlled
Rosuvastatin Multinational Trial
in Heart Failure) (5).
Methods
CORONA enrolled 5,011 pa-
tients who were at least 60 years of
age with symptomatic (NewYork Heart Association [NYHA] class II to IV), ischemic,
systolic (left ventricular ejection fraction [LVEF]: 40%) HF
(nomore than35% inpatients inNYHAclass II).The exclusion
criteria included uncontrolled hypothyroidism, as indicated by a
TSH level>2 times the upper limit of normal at enrollment visit
2, and concomitant conditions of clinical signiﬁcance, including
systemic disease (e.g., uncorrected hyperthyroidism or
amyloidosis). Patients were randomized to receive 10 mg of
rosuvastatin or matching placebo once daily (5). The ethics
committee at each of the participating hospitals approved the
trial, and patients provided written informed consent. The
primary composite outcome was death from cardiovascular
(CV) causes, nonfatal myocardial infarction, or nonfatal stroke.
The median follow-up was 32.8 months. Rosuvastatin therapy
did not reduce the primary outcome or death from any cause.
A total of 4,987 patients (99.5%) had a TSHmeasurement
available at baseline, 237 of which (4.8%) were not considered
because of baseline thyroid replacement therapy (TRT). As in
the SCD-HeFT analysis, patients were classiﬁed as euthyroid
if their TSH values were in the range of 0.3 to 5.0 mU/ml and
they were not taking TRT, hyperthyroid if their TSH levels
were <0.3 mU/ml and they were not taking TRT, or hypo-
thyroid if they had TSH levels of>5.0 mU/ml (and no TRT);
4,750 patients were included in the ﬁnal analyses.
We carried out a number of additional analyses including:
1) examination of the TSH categories listed above,
without accounting for TRT; 2) use of a TSH threshold of
>3.6 mU/ml to deﬁne hypothyroidism (6); 3) exclusion from
analysis of those patients who were taking amiodarone; and 4)
use of TSH as a continuous variable.
Statistical analysis. Baseline characteristics of euthyroid
patients were compared with those of hypothyroid patients;
comparisons between euthyroid and hyperthyroid patients
were made using analysis of variance (ANOVA) tests for con-
tinuous variables and chi-square tests for categorical variables.
The association between thyroid states and composite
outcome of CV death or hospitalization due to worsening HFwas testedusing time-to-event regression analyses on the basis of
Coxproportional hazardmodels.Other outcomes analyzedwere
the components of the composite (CV death and HF hospi-
talization individually) and all-cause death. Hyperthyroid and
hypothyroid stateswere tested simultaneouslywith indicators for
each in a multivariable model relative to those of the euthyroid
state. The covariates used were on the basis of previously re-
ported predictive models (see the footnote to Table 3; baseline
antiarrhythmic treatment was included as a covariate) (7).
Cumulative event curves are presented by thyroid state,
estimated using the Kaplan-Meier method and compared
with log-rank tests.
All p values are 2-sided, and a p value of <0.05 was consid-
ered signiﬁcant. All statistical analyses were performed using
Stata version 12 software (Stata Corp., College Station, Texas).
Results
Of the 4,750 patients with a TSH measurement and not
taking TRT who were available for analysis, 91.3% of pa-
tients were euthyroid, 5.0% were hypothyroid, and 3.7%
were hyperthyroid (Table 1, Fig. 1).
Patient characteristics. Compared with euthyroid patients,
those with a hypothyroid TSH level were more likely to have a
history of stroke and to have an implanted cardioverter
deﬁbrillator (ICD) or to be taking an antiarrhythmic drug;
they were less likely to smoke or to be taking a beta-blocker,
angiotensin-converting enzyme (ACE) inhibitor/angiotensin
receptor blocker. Hypothyroid patients also had worse renal
function and higher N-terminal pro-B-type natriuretic pep-
tide (NT-proBNP) levels (Table 1). Hyperthyroid patients
had a higher heart rate and were more likely to have an ICD,
to be taking an ACE inhibitor, and to smoke (Table 1).
Unadjusted outcomes. Patients with hypothyroid TSH
levels had signiﬁcantly higher all-cause andCVmortality rates
and showed a trend toward higher risk for hospitalization with
worsening HF; hypothyroid TSH level was associated with a
signiﬁcantly higher risk of the composite outcome of CV
death or HF hospitalization (Table 2, Fig. 2). There was no
association between a hyperthyroid TSH level and risk of
death or HF hospitalization (Table 2, Fig. 2).
Adjusted outcomes. Adjustment for other variables
(excludingNT-proBNP)associatedwithworse clinical outcomes
greatly weakened the relationship between hypothyroidism and
death and the composite outcome (Table 3). Addition of
NT-proBNP to these multivariable models eliminated the as-
sociation between hypothyroidism and outcomes.
The additional analyses using aTSHcut-off point of 3.6mU/
ml, excluding patients treated with amiodarone, not excluding
patients taking TRT and using TSH as a continuous variable,
yielded similar results (see the Online Appendix).
Discussion
Althoughwewere able to conﬁrm and extend theﬁndings of the
SCD-HeFT investigators regarding the association between
abnormal thyroid function and clinical outcomes in the
Table 1 Clinical Characteristics According to Baseline Thyroid Status Based Upon TSH Level
Variable
Euthyroid
(n ¼ 4,338)
Hypothyroid
(n ¼ 237)
Hyperthyroid
(n ¼ 175) p Value
Age, yrs 72.6  7.1 73.0  6.8 72.9  6.2 0.55
Age 70 yrs 64.5% (2,796) 67.1% (159) 72.0% (126) 0.08
Female 953 (22.0%) 55 (23.2%) 53 (30.3%) 0.03
Racial distribution
Caucasian 4,279 (98.6%) 234 (98.7%) 172 (98.3%) 0.66
Black 12 (0.3%) 1 (0.4%) 0 (0%)
Asian 30 (0.7%) 2 (0.8%) 1 (0.6%)
Other 17 (0.4%) 0 (0.0%) 2 (1.1%)
NYHA functional class III/IV 2,722 (62.8%) 151 (63.7%) 111 (63.4%) 0.94
LVEF 100 30.9  6.5 30.5  6.7 31.3  6.5 0.38
Systolic BP, mm Hg 129.3  16.5 128.3  16.4 130.3  15.5 0.45
Heart rate, beats/min 71.6  11.1 70.7  11.1 73.8  12.1 0.02
BMI, kg/m2 27.2  4.5 26.9  4.2 27.3  4.3 0.57
BMI >median (26.7 kg/m2) 2,203 (50.8%) 110 (46.4%) 89 (50.9%) 0.94
Current smoker 382 (8.8%) 11 (4.7%) 23 (13.1%) 0.01
Medical history
MI 2,612 (60.2%) 147 (62.0%) 91 (52.0%) 0.08
Angina pectoris 3,154 (72.7%) 158 (66.7%) 124 (70.9%) 0.12
CABG/PCI 1,113 (25.7%) 58 (24.5%) 54 (30.9%) 0.27
Hypertension 2,741 (63.2%) 157 (66.2%) 112 (64.0%) 0.63
Diabetes mellitus 1,283 (29.6%) 60 (25.3%) 56 (32.0%) 0.28
Baseline AF/F 1,021 (23.5%) 69 (29.1%) 45 (25.7%) 0.12
Stroke 529 (12.2%) 48 (20.3%) 14 (8.0%) <0.001
Pacemaker 467 (10.8%) 25 (10.6%) 23 (13.1%) 0.61
ICD 98 (2.3%) 13 (5.5%) 8 (4.6%) 0.002
Laboratory measurements
Cholesterol, mmol/l 5.35  1.08 5.40  1.17 5.28  1.13 0.57
ApoB:ApoA-1 ratio 0.87  0.25 0.91  0.26 0.88  0.25 0.07
Triglycerides, mmol/l 2.01  1.29 1.99  1.40 1.82  0.85 0.18
Serum creatinine, mmol/l 114.7  27.5 123.2  27.3 113.4  31.4 <0.001
Estimated GFR, ml/min/1.73 m2 56.8  15.0 51.8  13.6 57.5  16.9 <0.001
NT-proBNP, pmol/l 167.44
(69.74–362.73)
190.28
(103.1–433.3)
190.69
(92.54–309.75)
0.01
hs-CRP, mg/l 3.4 (1.5–7.3) 4.5 (1.8–9) 3.9 (1.7–7.0) 0.39
TSH, mU/ml 1.82  1.01 9.65  15.71 0.14  0.10 <0.001
Median (IQR) 1.6 (1.0–2.4) 6.4 (5.6–8.0) 0.14 (0.02–0.24)
Medication
Loop diuretic 3,265 (75.3%) 189 (79.8%) 133 (76.0%) 0.29
Loop or thiazide diuretic 3,809 (87.8%) 214 (90.3%) 156 (89.1%) 0.46
ACE inhibitor 3,477 (80.2%) 179 (75.5%) 155 (88.6%) 0.004
ACE inhibitor or ARB 3,983 (91.8%) 209 (88.2%) 166 (94.9%) 0.04
Beta-blocker 3,273 (75.5%) 160 (67.5%) 142 (81.1%) 0.004
Digitalis glycoside 1,428 (32.9%) 78 (32.9%) 63 (36.0%) 0.70
Antiarrhythmic therapy 476 (11.0%) 82 (34.6%) 25 (14.3%) <0.001
Antiplatelet therapy 2,603 (60.0%) 135 (57.0%) 95 (54.3%) 0.22
Anticoagulant therapy 1,507 (34.7%) 94 (39.7%) 65 (37.1%) 0.26
Antiplatelet or
anticoagulant therapy
3,926 (90.5%) 218 (92.0%) 152 (86.9%) 0.20
Values are mean  SD, % (n), or n (%).
ACE ¼ angiotensin-converting enzyme; AF/F ¼ atrial ﬁbrillation/ﬂutter; ApoA ¼ apolipoprotein; ApoB ¼ apolipoprotein B; ARB ¼ angiotensin
receptor blocker; BMI ¼ body mass index; bpm ¼ beats per minute; CABG ¼ coronary artery bypass graft; GFR ¼ glomerular ﬁltration rate; hs-CRP ¼
high-sensitivity C-reactive protein; ICD ¼ implanted cardioverter deﬁbrillator; IQR ¼ interquartile range; LVEF ¼ left ventricular ejection fraction; MI ¼
myocardial infarction; NT pro BNP ¼ N-terminal pro B type natriuretic peptide; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary
intervention; SD ¼ standard deviation; TSH ¼ thyroid-stimulating hormone.
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37CORONA study in unadjusted and partially adjusted analyses,
the relationship between TSH and prognosis was eliminated
when NT-proBNP was included in our multivariable models.In CORONA, as in SCD-HeFT (n ¼ 2,225), most
patients were euthyroid (91.3% and 87%, respectively),
although a slightly higher proportion in CORONA (5.0%
Figure 1 Distribution of Baseline TSH Values
Distribution of TSH levels (mU/ml) at baseline in CORONA patients with a left
ventricular ejection fraction of 35% or less. Intervals on the right of the graph
include a wider range of values due to the sparseness of data. TSH ¼ thyroid-
stimulating hormone.
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38vs. 1%, respectively) was hyperthyroid, and a lower pro-
portion were hypothyroid (3.5% vs. 12%, respectively). In
CORONA, only hypothyroid TSH values (and not hy-
perthyroid levels) were associated with increased mortality
(all-cause and CV mortality). In univariate analyses, hy-
pothyroid TSH level also tended to be associated with HF
hospitalization, an outcome not considered in SCD-
HeFT. Consequently, there was a strong, statistically sig-
niﬁcant association between hypothyroid TSH levels and
the composite outcome of CV death or HF hospitalization
(patients with hypothyroidism were 29% more likely to
experience this outcome than those who were euthyroid).
However, when these analyses were adjusted for other
known predictors of outcome (excluding NT-proBNP)
using previously constructed multivariable models (7), the
associations were greatly weakened (only CV death
remained close to statistically signiﬁcant). When NT-
proBNP was added to these models, the association be-
tween hypothyroidism and all outcomes was completely
eliminated. NT-proBNP was not measured in SCD-
HeFT and, therefore, could not be used in the multivari-
able model used to adjust for other predictors of death in
that trial.Table 2 Clinical Outcomes According to Baseline Thyroid Status Bas
Variable
Euthyroid
(n ¼ 4,338)
Hypothyroid
(n ¼ 237)
Hyperthy
(n ¼ 17
CV deaths or HF hospitalizations 1,668 (38.5) 111 (48.8) 62 (35.
CV deaths 997 (23.0) 76 (32.1) 31 (17.
HF hospitalizations 1096 (25.3) 69 (29.1) 45 (25.
All-cause deaths 1,266 (29.2) 90 (38.0) 46 (26.
Values are n (%).
CV ¼ cardiovascular; HF ¼ heart failure; TSH ¼ thyroid-stimulating hormone.Unlike SCD-HeFT, the present study did not ﬁnd a
signiﬁcant association between hyperthyroid TSH levels at
baseline and outcomes in CORONA, although the numbers
of patients with such levels was small in both trials (20 in
SCD-HeFT and 175 in CORONA), and the ﬁndings in
SCD-HeFT may have been due to chance. The only other
study we know of that has examined the relationship be-
tween thyroid status and outcomes in patients with HF is
the INH (Interdisciplinary Network Heart Failure) study
(3). Of the 758 patients analyzed (all with an LVEF
of 40%), 641 (85%) had normal TSH levels, 77 (10%) had
suppressed TSH levels (<0.3 mU/ml), and 40 (5%) had
elevated TSH levels (>4.0 mU/ml). In univariate analysis,
there was a trend toward higher mortality in patients with a
hyperthyroid TSH level (which was eliminated after
adjustment for age) but no association between an elevated
TSH and death.
Study limitations. One limitation of the CORONA,
SCD-HeFT, and INH studies is that each was a randomized
trial with speciﬁc inclusion and exclusion criteria. However,
collectively, they enrolled a broad spectrum of patients with
HF and reduced LVEF, including many elderly patients.
Although the INH study did not have speciﬁc thyroid
exclusion criteria, CORONA did (and likely SCD-HeFT
did, although it was not reported in trial publications).
Furthermore, clinical trials always recruit healthier patients
with less comorbidity and exclude the very elderly. For all
these reasons, a greater proportion of “real-world” patients
with HF are likely to have clearly deﬁned hypo- and hyper-
thyroidism, and these states could be predictive of clinical
outcomes, unlike the mainly mild or subclinical thyroid
dysfunction investigated in the 3 trials discussed. No study
has looked at the prognostic importance of thyroid
dysfunction in patients with HF and preserved EF.
Another limitation of this report (and that of the SCD-
HeFT analysis) is the impossibility of teasing out cause
and effect. In other words, the issue of whether hypothyroid
patients have indicators of poorer clinical status because
underactivity of the thyroid gland in some way worsens the
HF syndrome or because having worse HF leads to an un-
deractive thyroid is not clear. Alternatively, and in our view
most likely, is the question: Are certain clinical features more
common in both those likely to have an underactive thyroid
gland and worse HF status? There were key differences
between hypothyroid and euthyroid patients, includinged Upon TSH Level
roid
5)
HR (95% CI)
Versus Euthyroid
Hypothyroid p Value Hyperthyroid p Value
4) 1.29 (1.07–1.57) 0.008 0.93 (0.72–1.20) 0.591
7) 1.46 (1.16–1.84) 0.002 0.77 (0.53–1.09) 0.143
7) 1.23 (0.96–1.56) 0.102 1.03 (0.77–1.39) 0.823
3) 1.36 (1.03–1.76) 0.004 0.89 (0.67–1.20) 0.457
Figure 2 Clinical Outcomes According to Thyroid Status (Euthyroid, Hypothyroid, or Hyperthyroid) by Using Kaplan-Meier Curves
(A) Composite of CV death or HF hospitalization. (B) Cardiovascular death. (C) Heart failure hospitalization. (D) All-cause death. Y-axis ¼ proportion of patients; X-axis ¼ time
(years); p values were derived from univariate log-rank tests.
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39more renal dysfunction and higher NT-proBNP, which are
also more likely between patients with worse and those with
better HF status. In patients without HF, it is hyperthy-
roidism and not hypothyroidism, which is associated with
higher natriuretic peptide levels, suggesting that the higher
natriuretic peptide levels in our hypothyroid patients wereTable 3 Risk of Clinical Outcomes According to Thyroid Status After
Variable
Adjusted Outcome Excluding NT-proBNP*
Hypothyroid Hyperthyroid
HR (95% CI) p Value HR (95% CI) p
CV deaths or HF
hospitalizations
1.17 (0.96–1.44) 0.13 0.91 (0.70–1.19)
CV deaths 1.27 (0.99–1.63) 0.06 0.81 (0.56–1.18)
HF hospitalizations 1.13 (0.88–1.47) 0.34 0.93 (0.68–1.29)
All-cause deaths 1.17 (0.93–1.48) 0.17 0.85 (0.62–1.17)
*Adjusted for: age, sex, New York Heart Association class, left ventricular ejection fraction, body mass i
coronary artery bypass graft, percutaneous coronary intervention, aortic aneurysm, hypertension, dia
cardioversion deﬁbrillator, apolipoprotein A-1 and -B, creatinine, alanine aminotransferase, creatinine ki
CI ¼ conﬁdence interval; CV ¼ cardiovascular; HF ¼ heart failure; HR ¼ hazard ratio; NT-proBNP ¼ Nbecause they were sicker and not directly due to reduced
thyroid hormone level (8). An additional confounding
variable was the use of antiarrhythmic treatment (mainly
amiodarone), which is known to cause disturbances of thy-
roid function and is a marker of worse clinical status (in that
it is prescribed for atrial and ventricular arrhythmias),Adjustment for Other Prognostic Variables
Adjusted Outcome Including log (NT-proBNP)*
Hypothyroid Hyperthyroid
Value HR (95% CI) p Value HR (95% CI) p Value
0.48 1.02 (0.79–1.32) 0.18 1.01 (0.74–1.38) 0.93
0.27 1.11 (0.82–1.52) 0.50 0.90 (0.59–1.39) 0.64
0.68 1.00 (0.73–1.37) 0.99 1.15 (0.81–1.64) 0.43
0.32 1.02 (0.76–1.36) 0.89 0.96 (0.67–1.39) 0.83
ndex (kg/m2), systolic blood pressure, heart rate, smoking, myocardial infarction, angina pectoris,
betes, baseline atrial ﬁbrillation/ﬂutter, stroke, intermittent claudication, pacemaker, implanted
nase, triglyceride level, C-reactive protein, and antiarrhythmic treatment.
-terminal pro-B-type natriuretic peptide.
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40although our ﬁndings were unchanged after exclusion of
these patients. Another limitation is our inability to study
the “low T3 syndrome,” which, although characterized by a
normal TSH, may cause functional hypothyroidism (9,10).
Conclusions
Our results show that hypothyroidism, as identiﬁed by an
elevated TSH level, is uncommon in patients with HF
and is not an independent predictor of adverse clinical
outcomes.
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